Antibodies such as ipilimumab, which blocks CTLA-4, pembrolizumab and nivolumab, which block PD-1 in T cells, and atezolizumab, durvalumab and avelumab, which block PD-L1 on tumor cells, have been developed and approved by the FDA for solid tumors [98,99,100,101,102]. The gene discussed is CD274; the disease is neoplasm.